GLP-1 medications (and newer GLP-1/GIP options such as tirzepatide) have changed how clinicians treat obesity and related metabolic conditions. At the same time, social media “transformation” stories and a booming telehealth market can make it hard to tell what’s medically appropriate, what’s marketing, and what’s simply a human story about health. Below is a practical, health-first guide to who these medicines may help, when they may not be needed, and how to evaluate programs that offer them.
What GLP-1 (and GLP-1/GIP) drugs actually do
These medicines mimic gut hormones involved in appetite and blood-sugar regulation. In simple terms, they can:
- Reduce appetite and “food noise” for many people
- Slow gastric emptying, increasing feelings of fullness
- Improve insulin sensitivity and blood-glucose control (especially relevant in type 2 diabetes)
The result can be meaningful, sustained weight loss for some patients—particularly when paired with nutrition, physical activity, sleep support, and treatment of underlying conditions.
Who should consider GLP-1 weight-loss injections?
Doctors generally frame GLP-1 therapy as a treatment for medical obesity and its complications—not as a cosmetic shortcut. While exact prescribing criteria vary by country and product label, many clinical decisions follow a similar logic:
- People with obesity (often defined by BMI thresholds) who have struggled to lose weight with lifestyle measures alone
- People who are overweight with weight-related health risks such as prediabetes/type 2 diabetes, high blood pressure, sleep apnea, fatty liver disease, or elevated cardiovascular risk
- People for whom weight reduction meaningfully changes prognosis (for example, improving glycemic control or reducing cardiometabolic risk)
Just as important: clinicians consider whether someone can use the medication safely and sustainably, including follow-up, side-effect management, and the ability to maintain nutrition and muscle mass during weight loss.
When these medications may not be the right fit
GLP-1 therapy is not automatically appropriate just because someone wants to lose weight. Common reasons a clinician might pause or avoid prescribing include:
- Minimal medical need (weight loss sought primarily for appearance rather than health)
- Medical contraindications or high-risk history (your clinician will screen for these)
- Unaddressed eating-disorder symptoms or patterns that could worsen with appetite suppression
- Inability to access ongoing monitoring (weight-loss medication is a process, not a one-time purchase)
The goal is to balance potential benefits against side effects, cost, and the realities of long-term weight management.
Telehealth GLP-1 programs: what to check before enrolling
Telehealth can expand access, but quality varies widely. Before you pay for any GLP-1 or tirzepatide-based program, look for signals that it is practicing medicine—not just dispensing medication.
Green flags
- A real clinical intake that reviews medical history, current meds, and contraindications
- Baseline lab work or documented recent labs when appropriate
- Clear dosing plan with titration and what to do if side effects occur
- Ongoing follow-up (scheduled check-ins, messaging access, and a plan for refills)
- Nutrition and strength guidance to help protect muscle and meet protein/fiber needs
Red flags
- “No labs, no questions” prescribing or a checkout-style process
- Hidden pricing (membership fees, medication costs, compounding/shipping fees)
- Overpromising (“guaranteed” results, rapid extreme loss, no side effects)
- No plan for stopping (how to maintain results if medication is reduced or discontinued)
If a program won’t clearly explain what medication you’ll receive, how it’s sourced, and how you’ll be monitored, consider that a sign to step back and get an in-person second opinion.
Beyond weight loss: possible effects on cravings and alcohol use
Some patients and researchers are interested in whether GLP-1 or GLP-1/GIP drugs may reduce certain cravings, including alcohol cravings. While early signals and patient anecdotes are drawing attention, it’s best to treat this as an developing area rather than a guaranteed benefit. If alcohol use is a concern, the safest approach is to view GLP-1 therapy—if used at all—as adjunctive to evidence-based support (medical care, counseling, and addiction treatment resources), not a replacement.
The mental-health side of “sudden weight loss” stories
Public conversations often assume weight loss must be due to a medication like Ozempic. But weight can change for many reasons, including stress, grief, depression, changes in appetite, or illness. Celebrity accounts and personal stories have highlighted that weight loss is not always a sign of improved health—and that mental health can be the driver.
If you’re considering GLP-1 therapy, it’s worth asking: What’s my relationship with food and body image right now? Appetite suppression may feel like relief for some people, but for others it can intersect with anxiety, depression, or disordered eating patterns. The healthiest programs make room for mental well-being, not just scale changes.
How to talk to your clinician (a checklist)
Bring these questions to a primary care clinician or obesity-medicine specialist:
- What is my medical indication? (What health outcomes are we targeting?)
- What are the expected benefits for me? (Not averages—your situation.)
- What side effects should I anticipate and how will we manage them?
- How will we protect muscle mass? (Protein, resistance training, pace of loss.)
- What is the long-term plan? (Maintenance, dose changes, stopping strategy.)
- How does mental health fit in? (Screening, support, referrals if needed.)
Bottom line
GLP-1 and GLP-1/GIP medications can be transformative for people with obesity and metabolic risk—when prescribed thoughtfully and supported with follow-up care. The safest path is to treat them like any serious chronic-care tool: confirm medical need, choose a program that monitors you properly, and keep mental health in the conversation as much as diet and exercise.